Publications by authors named "C Lopez-Pedrera"
: Obesity is a frequent comorbidity in rheumatoid arthritis (RA). This condition may lead these patients to have poorer disease control and a worse response to some of the available treatments. : We aim to analyze the role of body mass index (BMI) in the clinical response to Janus kinase inhibitors (JAKis) in patients with RA.
View Article and Find Full Text PDFPredictors of Mortality in Antiphospholipid Antibody-Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository.
Arthritis Care Res (Hoboken)
February 2025
Objective: The objective was to determine the mortality rate as well as the causes and predictors of death in antiphospholipid antibody (aPL)-positive patients with and without antiphospholipid syndrome (APS) classification.
Methods: The inclusion criterion for the multicenter international Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) registry is positive aPLs according to the Revised Sapporo Classification Criteria tested within one year before enrollment. Patients are observed every 12 ± 3 months with clinical data and blood collection.
Article Synopsis
- - This study examined the occurrence and effects of antinuclear antibodies (ANA) in patients with antiphospholipid antibodies (aPL) but without other systemic autoimmune diseases, using data from the APS ACTION Registry.
- - Among the 430 analyzed patients, 56% tested positive for ANA, revealing significant links between ANA positivity and various autoimmune features like hematologic issues and joint involvement.
- - Despite the presence of these autoimmune characteristics in ANA-positive patients, the study found no connection between ANA status and complications related to thrombosis or pregnancy; interestingly, ANA-negative patients had more pregnancies and live births.
Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs.
Biomed Pharmacother
April 2024
Article Synopsis
- The study investigated the inflammatory profiles of Rheumatoid Arthritis (RA) patients to identify those at higher risk for cardiovascular (CV) issues and evaluated the effects of specific medications.
- Researchers analyzed data from 387 RA patients, dividing them into groups based on prior CV events and treatment with disease-modifying drugs, while examining various inflammatory biomarkers.
- Findings revealed three distinct RA patient groups with varying inflammatory levels and CV risks, highlighting that certain treatments effectively lowered disease activity and improved inflammatory markers associated with CV risk, suggesting a pathway for personalized management in RA care.
Introduction: RA patients are at higher risk of cardiovascular disease, influenced by therapies. Studying their cardiovascular and cardiometabolic proteome can unveil biomarkers and insights into related biological pathways.
Methods: This study included two cohorts of RA patients: newly diagnosed individuals (n=25) and those with established RA (disease duration >25 years, n=25).